...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.
【24h】

Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.

机译：胃腺癌患者FHIT蛋白表达的临床病理意义。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma. METHODS: FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis. RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa. There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000). FHIT protein expression was found in 64.3% (18/28) of grades I and II cancers, and 20.8% (10/48) of grade III cancers (P = 0.000), in 56.3% (18/32) of stages I and II cancers and 22.7% (10/44) of stages III and IV cancers (P = 0.004), and in 63.6% (14/22) of cancers without metastasis but only 25.9% (14/54) of those with metastasis (P = 0.003). The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer. Follow-up data showed that there was a significant difference in median survival time between cancer patients with expression of FHIT (71 mo) and those without (33 mo, log rank = 20.78, P = 0.000). CONCLUSION: FHIT protein is an important tumor suppressor protein. Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
机译：目的：探讨脆性组氨酸三联体（FHIT）蛋白的表达及其在胃癌中的表达与临床病理指标的可能关系。方法：采用免疫组织化学方法检测76例胃癌，58例上皮内瘤样病变和76例相应的正常黏膜组织中FHIT蛋白的表达，并分析其与组织学分级，临床分期，转移状况及预后的关系。结果：FHIT蛋白表达在腺癌组织中占28/76（36.8％），在邻近的异常增生组织中占22/58（37.9％），在远端正常胃黏膜中占76/76（100％）。在癌或邻近的上皮内瘤变与正常胃粘膜之间，FHIT蛋白的表达存在显着差异（P = 0.000）。 FHIT蛋白表达在I级和II级癌症中占64.3％（18/28），在III级癌症（P = 0.000）中占20.8％（10/48），在I和II期癌症中占56.3％（18/32）。 II类癌症和22.7％（10/44）的III和IV期癌症（P = 0.004），以及63.6％（14/22）没有转移的癌症，但只有25.9％（14/54）有转移的癌症（P = 0.003）。在癌的组织学等级，临床分期和转移状态之间发现FHIT表达的显着差异。随访数据显示，有FHIT表达的癌症患者（71 mo）和没有FHIT表达的癌症患者（33 mo，对数秩= 20.78，P = 0.000）之间的中位生存时间有显着差异。结论：FHIT蛋白是一种重要的肿瘤抑制蛋白。 FHIT蛋白表达的丧失可能与胃腺癌的发生，侵袭，转移和预后有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号